JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models

被引：0

作者：

Hauptschein, Robert ^{[1
]}

Woodcock, Simon ^{[2
]}

Belfield, Andrew ^{[2
]}

Mason, Helen ^{[2
]}

Keppel, Dorottya ^{[2
]}

Markova, Svetlana ^{[1
]}

Kim, Kyuri ^{[1
]}

Roller, Shane ^{[1
]}

Phillips, Caroline ^{[2
]}

Jones, Clifford D. ^{[2
]}

Humphreys, Robin C. ^{[1
]}

机构：

[1] Jazz Pharmaceut, Palo Alto, CA USA

[2] Redx Pharma, Manchester, Lancs, England

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2677

引用

页数：1

共 50 条

[41] Amdizalisib (HMPL-689), a highly selective PI3Kd inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models
Hu, Jia
Wang, Jianhan
Dai, Xiaoming
He, Jianlin
Liang, Junqing
Yu, Ying
Yu, Juntao
Yang, Na
Wang, Linfang
Cai, Yu
Li, Xiong
Qing, Weiguo
Ren, Yongxin
Su, Weiguo
CANCER RESEARCH, 2022, 82 (12)
[42] Design and rationale of a first in human (FIH) phase 1/1b study evaluating KIN-2787, a potent and highly selective pan-RAF inhibitor, in adult patients with BRAF- and NRAS-mutation positive solid tumors.
McKean, Meredith
Perez, Cesar A.
Kato, Shumei
Spira, Alexander I.
Xing, Yan
Xie, Hao
Millward, Michael
Olszanski, Anthony
Kobayashi, Ken
Miller, Nichol
Severson, Paul
Tam, Betty
Unger, Caro
CANCER RESEARCH, 2022, 82 (12)
[43] Efficacy advantages of a novel pan-RAS inhibitor, ADT-1004, over mutant- specific KRAS inhibitors for suppressing pancreatic tumor growth in murine models
Bandi, Dhana Sekhar Reddy
Nagaraju, Ganji P.
Foote, Jeremy B.
Keeton, Adam B.
Chen, Xi
Berry, Kristy L.
Maxuitenko, Yulia Y.
Manne, Upender
Buchsbaum, Donald J.
Piazza, Gary A.
El-Rayes, Bassel F.
CANCER RESEARCH, 2024, 84 (17)
[44] ABN401 demonstrates robust anti-tumor efficacy in orthotopic PDX models of MET-driven NSCLC brain metastases in a pre-clinical study
Rajasekaran, Nirmal
Park, Kyung Eui
Lee, Saehyung
Kim, Na Young
Chung, Suk-Jae
Shin, Young Kee
Choi, Jun Young
CANCER RESEARCH, 2023, 83 (07)
[45] The FHP01 DDX3X Helicase Inhibitor Exerts Potent Anti-Tumor Activity In Vivo in Breast Cancer Pre-Clinical Models
Gherardini, Lisa
Inzalaco, Giovanni
Imperatore, Francesco
D'Aurizio, Romina
Franci, Lorenzo
Miragliotta, Vincenzo
Boccuto, Adele
Calandro, Pierpaolo
Andreini, Matteo
Tarditi, Alessia
Chiariello, Mario
CANCERS, 2021, 13 (19)
[46] GDC-0214 Is a Potent Inhaled JAK Inhibitor With Efficacy in Multiple Pre-clinical Models of Th2 Inflammation: A Perspective on Use of In Vivo Rodent Models for Early Phase Drug Discovery
Eller, C. Rinderknecht
Rardin, H.
Sambamurthy, N.
Thadani, C.
Wu, X.
Liu, J.
Suto, E.
Gulati, I.
Zhang, J.
Kallapur, K.
Kim, C.
Tan, S.
Wang, L.
Yanez, E.
Reiss, A.
Zhang, X.
Dale, S.
Cui, Y.
Lee, W.
Sethuraman, V.
Wilson, M.
Johnson, A.
Ning, M.
Grandner, J.
Briggs, M.
Rajapaksa, N.
Durk, M.
Wright, M.
Zak, M.
Kenny, J.
Ghilardi, N.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[47] Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Nishiguchi, Gisele A.
Rico, Alice
Tanner, Huw
Aversa, Robert J.
Taft, Benjamin R.
Subramanian, Sharadha
Setti, Lina
Burger, Matthew T.
Wan, Lifeng
Tamez, Victoriano
Smith, Aaron
Lou, Yan
Barsanti, Paul A.
Appleton, Brent A.
Mamo, Mulugeta
Tandeske, Laura
Dix, Ina
Tellew, John E.
Huang, Shenlin
Griner, Lesley A. Mathews
Cooke, Vesselina G.
Van Abbema, Anne
Merritt, Hanne
Ma, Sylvia
Gampa, Kalyani
Feng, Fei
Yuan, Jing
Wang, Yingyun
Haling, Jacob R.
Vaziri, Sepideh
Hekmat-Nejad, Mohammad
Jansen, Johanna M.
Polyakov, Valery
Zang, Richard
Sethuraman, Vijay
Amiri, Payman
Singh, Mallika
Lees, Emma
Shao, Wenlin
Stuart, Darrin D.
Dillon, Michael P.
Ramurthy, Savithri
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (12) : 4869 - 4881
[48] VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells
Kolev, V.
Wang, Y.
Sprott, K.
Padval, M.
Pachter, J.
Weaver, D.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S53 - S53
[49] An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
Chen, Xin
Xue, Liu
Ding, Xiao
Zhang, Jing
Jiang, Lei
Liu, Sha
Hou, Hongjia
Jiang, Bin
Cheng, Liang
Zhu, Qing
Zhang, Lijie
Zhou, Xiaosui
Ma, Jie
Liu, Qi
Li, Yucheng
Ren, Zhiying
Jiang, Beibei
Song, Xiaomin
Song, Jing
Jin, Wei
Wei, Min
Shen, Zhirong
Liu, Xuesong
Wang, Lai
Li, Kang
Zhang, Tong
FRONTIERS IN IMMUNOLOGY, 2022, 13
[50] A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models.
Chen, Xin
Xue, Liu
Ding, Xiao
Liu, Qi
Zhang, Jing
Jiang, Lei
Liu, Sha
Hou, Hongjia
Zhu, Qing
Jiang, Bin
Zhang, Lijie
Zhou, Xiaosui
Ma, Jie
Li, Yucheng
Jin, Wei
Wei, Min
Shen, Zhirong
Liu, Mike
Li, Kang
Zhang, Tong
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →